Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole or Rifampin on BMS-986205 PK
NCT03346837Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linrodostat in solid tumor (4 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 25 days, AUC from time zero to time of last quantifiable concentration up to 25 days and 1 more. Started Nov 2017; status: completed.
02
Drugs
linrodostat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03346837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03346837.